However, a pharmacovigilance study using the WHO's global adverse drug reaction database found disproportionate reporting of eating disorder adverse events with all three major GLP-1 medications ( Nishida et al., Clinical Nutrition, 2025 )
Pharmacokinetically, BPC-157 has a relatively short plasma half-life estimated at 10-15 minutes when administered parenterally, though its tissue-level effects persist far longer due to receptor-level interactions and growth factor cascading
Meet with a provider by video
Notably, even 2.5 M SFN, a concentration that can be found in human serum after broccoli sprout consumption, was sufficient to dampen the expression of CD25 (and slightly CD69) on the surface of T-cells
You trade known effects for uncertainty and potential danger when you: Change dose Frequency Formulation Handling outside-tested protocols Absence Of Clinical Trials And Safety Data For Microdoses Medicines like Tirzepatide go through a lot of testing before doctors can give them to people